GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncodesign Precision Medicine SA (XPAR:ALOPM) » Definitions » Change In Receivables

Oncodesign Precision Medicine (XPAR:ALOPM) Change In Receivables : €0.00 Mil (TTM As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Oncodesign Precision Medicine Change In Receivables?

Oncodesign Precision Medicine's change in receivables for the quarter that ended in Dec. 2024 was €0.00 Mil. It means Oncodesign Precision Medicine's Accounts Receivable stayed the same from Jun. 2024 to Dec. 2024 .

Oncodesign Precision Medicine's change in receivables for the fiscal year that ended in Dec. 2024 was €0.00 Mil. It means Oncodesign Precision Medicine's Accounts Receivable stayed the same from Dec. 2023 to Dec. 2024 .

Oncodesign Precision Medicine's Accounts Receivable for the quarter that ended in Dec. 2024 was €0.62 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Oncodesign Precision Medicine's liquidation value for the six months ended in Dec. 2024 was €-5.40 Mil.

Oncodesign Precision Medicine Change In Receivables Historical Data

The historical data trend for Oncodesign Precision Medicine's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncodesign Precision Medicine Change In Receivables Chart

Oncodesign Precision Medicine Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Change In Receivables
- - - - -

Oncodesign Precision Medicine Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Change In Receivables Get a 7-Day Free Trial - - - - -

Oncodesign Precision Medicine Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oncodesign Precision Medicine  (XPAR:ALOPM) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Oncodesign Precision Medicine's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0.624/0*91
=

2. In Ben Graham's calculation of liquidation value, Oncodesign Precision Medicine's accounts receivable are only considered to be worth 75% of book value:

Oncodesign Precision Medicine's liquidation value for the quarter that ended in Dec. 2024 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=5.277-11.14+0.75 * 0.624+0.5 * 0
=-5.40

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oncodesign Precision Medicine Change In Receivables Related Terms

Thank you for viewing the detailed overview of Oncodesign Precision Medicine's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Oncodesign Precision Medicine Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncodesign Precision Medicine SA (XPAR:ALOPM) » Definitions » Change In Receivables
Comparable Companies
XPAR:ALTME XPAR:ALTAO XPAR:ALVIO XPAR:ALINT XPAR:ALBPS XPAR:ALTHX XPAR:ALPAT XPAR:ALMDP XPAR:ALNEV XPAR:ALNFL VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
N/A
Address
18 rue Jean Mazen, Dijon, FRA, 21000
Website
https://www.opm.oncodesign.com
Oncodesign Precision Medicine SA is a biopharmaceutical company specialised in precision medicine. Its mission is to provide patients with effective diagnostic and therapeutic solutions for resistant and metastatic cancers.

Oncodesign Precision Medicine Headlines

No Headlines